FABP3 and metabolic syndrome: As pharmacological improvement of dyslipidemia with Simvastatin could ameliorate progression of obesity/diabetic nephropathy, we used the Simvastatin-treated mouse model to test its effect on H-FABP expression in cases of ORG.